Cargando…
The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
BACKGROUND: Anti-angiogenesis therapy has been a vital treatment option in a variety of cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer is essential. METHODS: Thirty patients with end-stage cancer who were heavily pretreated were enrolled i...
Autores principales: | Li, Zhenyu, Zhou, Xiaoshu, Wang, Shuai, Shi, Liangliang, Meng, Rui, Dai, Xiaofang, Liu, Yi, Lin, Xueke, Xiao, Yong, Peng, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174995/ https://www.ncbi.nlm.nih.gov/pubmed/37180651 http://dx.doi.org/10.21037/tcr-22-2080 |
Ejemplares similares
-
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022) -
Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023) -
Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014) -
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
por: Zhu, Anjie, et al.
Publicado: (2021) -
Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
por: Yang, Dexiang, et al.
Publicado: (2018)